Atezolizumab+Bevacizumab+SBRT in Unresectable HCC

This study is testing a combination of atezolizumab (immunotherapy), bevacizumab (a drug that blocks tumor blood vessel growth), and targeted radiation (SBRT) for people with liver cancer (hepatocellular carcinoma) that cannot be removed by surgery and has not yet been treated with systemic therapy. **You may be eligible if...** - You have been diagnosed with hepatocellular carcinoma (liver cancer) confirmed by biopsy or imaging - Your cancer is deemed not suitable for surgery, transplant, or ablation - You have up to 5 tumor lesions, with no single lesion larger than 15 cm and total size under 20 cm - Your liver function is adequate (Child-Pugh A or B7) - You have not previously received systemic drug treatment for this cancer **You may NOT be eligible if...** - You have received prior immunotherapy or anti-VEGF treatment - You have active autoimmune disease - You are pregnant or breastfeeding - You have significant bleeding risk (e.g., esophageal varices) - Your liver disease is too advanced (Child-Pugh C) Talk to your doctor to see if this trial is right for you.